Aslan Pharmaceuticals Ltd
NASDAQ:ASLN
Income Statement
Earnings Waterfall
Aslan Pharmaceuticals Ltd
Revenue
|
12m
USD
|
Cost of Revenue
|
0
USD
|
Gross Profit
|
12m
USD
|
Operating Expenses
|
-24.8m
USD
|
Operating Income
|
-12.8m
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
-11.6m
USD
|
Income Statement
Aslan Pharmaceuticals Ltd
Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||
Revenue |
0
N/A
|
10
+4 092%
|
12
+10%
|
11
-9%
|
10
-2%
|
0
-100%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
3
N/A
|
3
N/A
|
3
N/A
|
3
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
12
N/A
|
12
N/A
|
|
Gross Profit | ||||||||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Gross Profit |
0
N/A
|
0
N/A
|
11
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
3
N/A
|
3
N/A
|
3
N/A
|
3
+1%
|
0
-99%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
12
N/A
|
12
N/A
|
|
Operating Income | ||||||||||||||||||||||||||||
Operating Expenses |
(14)
|
(15)
|
(20)
|
(16)
|
(22)
|
(25)
|
(39)
|
(40)
|
(42)
|
(46)
|
(42)
|
(41)
|
(36)
|
(30)
|
(25)
|
(45)
|
(41)
|
(40)
|
(16)
|
(20)
|
(24)
|
(29)
|
(34)
|
(37)
|
(43)
|
(14)
|
(25)
|
|
Selling, General & Administrative |
(7)
|
(7)
|
(7)
|
(5)
|
(6)
|
(6)
|
(9)
|
(10)
|
(11)
|
(12)
|
(11)
|
(10)
|
(9)
|
(7)
|
(9)
|
(7)
|
(7)
|
(7)
|
(7)
|
(9)
|
(11)
|
(13)
|
(12)
|
(11)
|
(10)
|
(3)
|
(6)
|
|
Research & Development |
(7)
|
(8)
|
(13)
|
(11)
|
(16)
|
(19)
|
(30)
|
(29)
|
(31)
|
(34)
|
(32)
|
(31)
|
(28)
|
(23)
|
(17)
|
(14)
|
(11)
|
(9)
|
(9)
|
(11)
|
(13)
|
(16)
|
(22)
|
(28)
|
(34)
|
(12)
|
(19)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(23)
|
(23)
|
(23)
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
Operating Income |
(14)
N/A
|
(5)
+67%
|
(9)
-84%
|
(6)
+32%
|
(12)
-95%
|
(25)
-115%
|
(39)
-57%
|
(40)
-2%
|
(42)
-6%
|
(46)
-8%
|
(42)
+7%
|
(38)
+10%
|
(34)
+11%
|
(28)
+18%
|
(23)
+19%
|
(45)
-99%
|
(41)
+8%
|
(40)
+4%
|
(16)
+58%
|
(20)
-21%
|
(24)
-21%
|
(29)
-19%
|
(34)
-18%
|
(37)
-8%
|
(43)
-19%
|
(2)
+95%
|
(13)
-441%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||
Interest Income Expense |
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(3)
|
(4)
|
(1)
|
(2)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(23)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
2
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
1
|
1
|
2
|
2
|
1
|
2
|
1
|
2
|
3
|
|
Pre-Tax Income |
(15)
N/A
|
(6)
+60%
|
(9)
-49%
|
(6)
+29%
|
(12)
-92%
|
(26)
-107%
|
(40)
-56%
|
(40)
-2%
|
(42)
-5%
|
(45)
-8%
|
(42)
+7%
|
(38)
+11%
|
(34)
+10%
|
(28)
+17%
|
(47)
-65%
|
(46)
+2%
|
(42)
+7%
|
(41)
+3%
|
(17)
+58%
|
(21)
-22%
|
(24)
-14%
|
(28)
-19%
|
(32)
-12%
|
(38)
-19%
|
(44)
-16%
|
(2)
+96%
|
(12)
-530%
|
|
Net Income | ||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
|
Income from Continuing Operations |
(15)
|
(6)
|
(9)
|
(6)
|
(12)
|
(26)
|
(40)
|
(40)
|
(42)
|
(46)
|
(42)
|
(38)
|
(35)
|
(29)
|
(47)
|
(46)
|
(42)
|
(41)
|
(17)
|
(21)
|
(24)
|
(28)
|
(32)
|
(38)
|
(44)
|
(2)
|
(12)
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
(15)
N/A
|
(6)
+60%
|
(9)
-49%
|
(6)
+29%
|
(12)
-92%
|
(26)
-107%
|
(40)
-56%
|
(40)
-2%
|
(42)
-5%
|
(46)
-8%
|
(42)
+7%
|
(38)
+11%
|
(35)
+8%
|
(29)
+17%
|
(47)
-64%
|
(46)
+3%
|
(42)
+9%
|
(40)
+4%
|
(16)
+60%
|
(20)
-23%
|
(23)
-16%
|
(28)
-22%
|
(31)
-11%
|
(38)
-20%
|
(43)
-16%
|
(2)
+96%
|
(12)
-515%
|
|
EPS (Diluted) |
-0.78
N/A
|
-0.26
+67%
|
-0.43
-65%
|
-0.27
+37%
|
-0.51
-89%
|
-0.97
-90%
|
-1.6
-65%
|
-1.55
+3%
|
-1.42
+8%
|
-1.42
N/A
|
-1.41
+1%
|
-1.17
+17%
|
-1.09
+7%
|
-0.9
+17%
|
-1.45
-61%
|
-1.2
+17%
|
-1.09
+9%
|
-1.05
+4%
|
-0.42
+60%
|
-0.38
+10%
|
-0.27
+29%
|
-0.4
-48%
|
-0.48
-20%
|
-0.52
-8%
|
-0.06
+88%
|
0
N/A
|
-0.03
N/A
|